PDS Biotechnology Corp Finance Lease, Liability, Undiscounted Excess Amount
PDS Biotechnology Corp (PDSB) had Finance Lease, Liability, Undiscounted Excess Amount of $2.63 thousand as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2026-08-13
- 2026-06-30: Finance Lease, Liability, Undiscounted Excess Amount $2.63K.
- 2026-03-31: Finance Lease, Liability, Undiscounted Excess Amount $3.69K.
- 2025-12-31: Finance Lease, Liability, Undiscounted Excess Amount $4.98K.
- 2025-09-30: Finance Lease, Liability, Undiscounted Excess Amount $6.63K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2026-06-30 | $2.63K 10-Q · filed 2026-08-13 |
| 2026-03-31 | $3.69K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $4.98K 10-K · filed 2026-03-30 |
| 2025-09-30 | $6.63K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $8.65K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $11.01K 10-Q · filed 2025-05-14 |
| 2024-12-31 | $13.71K 10-K · filed 2025-03-27 |
| 2024-09-30 | $16.74K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $20.10K 10-Q · filed 2024-08-13 |
| 2024-03-31 | $23.77K 10-Q · filed 2024-05-15 |
| 2023-12-31 | $27.76K 10-K · filed 2024-03-28 |
| 2023-09-30 | $32.06K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $36.64K 10-Q · filed 2023-08-14 |
| 2023-03-31 | $41.52K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $42.33K 10-K · filed 2023-03-28 |
| 2022-09-30 | $18.21K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |